Browse
Submit Data
Databases
API
Help

Metabolomics,Unknown,Transcriptomics,Genomics,Proteomics

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Transcriptional profile of pimozide-treated cancer cell lines MIA PaCa-2, PANC-1, HT-29, HCT 116, SK-OV-3, OVCAR-5, AGS, MKN45 and DMSO-treated (as control)

ABSTRACT: DRD2 antagonists are commonly used clinically for the treatment of psychiatric disorders. This study aimed to explore the antitumor effects of DRD2 antagonists on a variety of tumor entities. A DRD2 antagonist, pimozide, exhibited antitumor effects in pancreatic, colorectal, ovarian, and gastric cancers. HMOX1 was found to be highly expressed at both mRNA and protein levels, corroborating the results of profiling.

ORGANISM(S): Homo sapiens

SUBMITTER: Mei Mei

PROVIDER: E-MTAB-15350 | biostudies-arrayexpress |

REPOSITORIES: biostudies-arrayexpress

ACCESS DATA

Json Xml

Similar Datasets

Transcriptional profile of knockdown of HMOX1 or/and pimozide-treated cancer cell lines

Project description:DRD2 antagonists are commonly used clinically for the treatment of psychiatric disorders. This study aimed to explore the antitumor effects of DRD2 antagonists on a variety of tumor entities. A DRD2 antagonist, pimozide, exhibited antitumor effects in pancreatic, colorectal, ovarian, and gastric cancers. HMOX1 was found to be highly expressed at both mRNA and protein levels, corroborating the results of profiling. Transcriptional profile of knockdown of HMOX1 or/and pimozide-treated cancer cell lines was showed then.

2025-08-30 | E-MTAB-15496 | biostudies-arrayexpress

Transcriptional profile of overexpression of HMOX1 or/and pimozide-treated cancer cell lines MIA PaCa-2, HCT 116, SK-OV-3, and AGS

Project description:DRD2 antagonists are commonly used clinically for the treatment of psychiatric disorders. This study aimed to explore the antitumor effects of DRD2 antagonists on a variety of tumor entities. A DRD2 antagonist, pimozide, exhibited antitumor effects in pancreatic, colorectal, ovarian, and gastric cancers. HMOX1 was found to be highly expressed at both mRNA and protein levels, corroborating the results of profiling. The treatment of pimozide and overexpression of HMOX1 experiments were conducted then.

2025-08-30 | E-MTAB-15495 | biostudies-arrayexpress

Methylome of a low-grade invasive GIST

Project description:A low-grade invasive gastro-intestinal stromal tumour (GIST) was subjected to whole-genome sequencing as well as methylation profiling using Illumina 450K BeadChip array, in order to determine the minimal set of genomic and epigenomic alterations necessary to trigger the formation of invasive GIST. single-sample study, DNA extracted from fresh frozen tissue.

2014-08-01 | E-GEOD-55521 | biostudies-arrayexpress

Comparison of C57BL/6 and Dkk3-/- purified B1 and B2 cells

Project description:B2 cells were purified from spleen by CD19 Microbeads. B1 cells were purified from peritoneal cavity lavage by CD19 microbeads, followed by a depletion of CD23+ cells. RNA was prepared and differential gene expression analysis performed.

2014-08-19 | E-MTAB-2850 | biostudies-arrayexpress

Methylation data of 20 samples of human lung adenocarcinoma brain metastases

Project description:Methylation status of lung adenocarcinoma brain metastases was analyzed as part of an approach to defining the microenvironment

2020-01-04 | E-MTAB-8660 | biostudies-arrayexpress

Transcriptomic analysis of aggressive meningiomas identifies PTTG1 and LEPR1 as prognostic biomarkers independent of WHO grade

Project description:Meningiomas are frequent central nervous system tumors. Although most meningiomas are benign (WHO grade I) and curable by surgery, WHO grade II and III tumors remain therapeutically challenging due to frequent recurrence. Interestingly, relapse also occurs in some WHO grade I meningiomas. Hence, we investigated the transcriptional features defining aggressive (recurrent, malignantly progressing or WHO grade III) meningiomas in 144 cases. Meningiomas were categorized into non-recurrent (NR), recurrent (R), and tumors undergoing malignant progression (M) in addition to their WHO grade. Unsupervised transcriptomic analysis in 62 meningiomas revealed transcriptional profiles lining up according to WHO grade and clinical subgroup. Notably aggressive subgroups (R+M tumors and WHO grade III) shared a large set of differentially expressed genes (n=332; p<0.01, FC>1.25). In an independent multicenter validation set (n=82), differential expression of 10 genes between WHO grades was confirmed. Additionally, among WHO grade I tumors differential expression between NR and aggressive R+M tumors was af rmed for PTTG1, AURKB, ECT2, UBE2C and PRC1, while MN1 and LEPR discriminated between NR and R+M WHO grade II tumors. Univariate survival analysis revealed a significant association with progression-free survival for PTTG1, LEPR, MN1, ECT2, PRC1, COX10, UBE2C expression, while multivariate analysis identified a prediction for PTTG1 and LEPR mRNA expression independent of gender, WHO grade and extent of resection. Finally, stainings of PTTG1 and LEPR confirmed malignancy-associated protein expression changes. In conclusion, based on the so far largest study sample of WHO grade III and recurrent meningiomas we report a comprehensive transcriptional landscape and two prognostic markers. Comparative transcriptomic analysis of 62 low- and high-grade meningiomas

2016-02-15 | E-GEOD-74385 | biostudies-arrayexpress

Transcription profiling by array of siRNA transfected HEK293T cells untreated or treated with TNF-alpha to study the effect of siRNA-mediated knockdown of different genes

Project description:HEK293T cells were treated with TNF-alpha for different periods of time to study the effect of siRNA-mediated knockdown of different genes (negative control: Renilla luciferase; positive controls: TNFRSF1A, RelA; gene of interest: CASP4) on TNF-induced gene expression

2012-07-06 | E-MTAB-900 | biostudies-arrayexpress

Metabolic and transcriptional changes following two, four and six weeks following TAC and Sham Surgery

Project description:Eight-week-old male mice (C57BL/6N) were randomly subjected to isolated thoracotomy (ITH) or transaortic banding (TAC). Healthy littermates were used as controls. Mice were sacrificed after 2 weeks, 4 weeks , and 6 weeks. All mice were assessed by echocardiography. Animals were fed ad libitum with Rod 16-A (LASvendi) and housed in a specific pathogen free environment as previously described. Microarray and metabolic panales were performed for all animals.

2020-06-01 | E-MTAB-8910 | biostudies-arrayexpress

LncRNA NEAT1 promotes immunosuppression in gastric cancer by maintaining the m6A methylation of SEMA3A in CAFs via exosomes under endoplasmic reticulum stress

Project description:Endoplasmic reticulum stress (ERS) regulates the function of immune cells in the tumor microenvironment and suppresses the antitumor immune response. In order to formulate the TME of ERS-GC, we cocultured the human CAFs with the supernatant of human gastric cancer cells stimulated by TM. Mass spectrometry sequencing revealed that ERS state regulated the overexpression of 58 proteins and downregulation of the expression of 56 proteins in CAFs, including m6A-modified proteins and SEMA3A, an immunosuppression-related protein.

2026-04-13 | PXD061686 | Pride

IL-17A influences essential functions of the monocyte / macrophage lineage and is involved in advanced murine and human atherosclerosis

Project description:Atherosclerosis is a chronic inflammatory disease. Lesion progression is primarily mediated by cells of the monocyte/macrophage lineage. Interleukin-17A is a pro-inflammatory cytokine, which modulates immune cell trafficking and is involved inflammation in (auto)immune and infectious diseases. But the role of IL-17A still remains controversial. In the current study we investigated effects of IL-17A on advanced murine and human atherosclerosis, the common disease phenotype in clinical care. 26-weeks old apolipoprotein E-deficient (Apoe-/-) mice were fed a standard chow diet and treated either with IL-17A mAb (n=15) or irrelevant immunoglobulin (n=10) for 16 weeks. Furthermore, essential mechanisms of IL-17A in atherogenesis were studied in vitro. Inhibition of IL-17A markedly prevented atherosclerotic lesion progression (P=0.001) by reducing inflammatory burden and cellular infiltration (P=0.01) and improved lesion stability (P=0.01). In vitro experiments showed that IL-17A plays a role in chemoattractance, monocyte adhesion, sensitization of antigen-presenting cells toward pathogen-derived TLR4 ligands. Also, IL-17A induced a unique transcriptome pattern in monocyte-derived macrophages distinct from known macrophage types. Stimulation of human carotid plaque tissue ex vivo with IL-17A induced a pro-inflammatory milieu and up-regulation of molecules expressed by the IL-17A-induced macrophage subtype. We here show for the first time that functional blockade of IL-17A prevents atherosclerotic lesion progression and induces plaque stabilization in advanced lesions in Apoe-/- mice. The underlying mechanisms involve reduced inflammation and distinct effects of IL-17A on monocyte / macrophage lineage. In addition, translational experiments underline the relevance for the human system. Effects of IL-17A on human monocyte-derived macrophages were assessed (n=2 per group).

2014-10-01 | E-GEOD-60824 | biostudies-arrayexpress

OmicsDI is part of the ELIXIR infrastructure

OmicsDI is an Elixir interoperability service. Learn more ›

Tweets

OmicsDI Databases

PRIDE
PeptideAtlas
MassIVE
JPOST Repository
Physiome Model Repository

EGA
EVA
ENA
LINCS
PAXDB
Cell Collective

MetaboLights
Metabolomics Workbench
MetabolomeExpress
GNPS
BioModels
FAIRDOMHub

ArrayExpress
dbGaP
ExpressionAtlas
GEO
NODE

Information

Databases
Help
API
Contact us
Code on GitHub
Terms of use
Submit Data